1
|
Dokic M, Urosevic I, Savic I, Sekulic B, Savic A, Milosevic I, Rajic N. A Case of Chronic Lymphocytic Leukaemia Occurring During Treatment of Chronic Myeloid Leukaemia. Indian J Hematol Blood Transfus 2016; 32:156-8. [PMID: 27408380 DOI: 10.1007/s12288-016-0638-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2015] [Accepted: 01/05/2016] [Indexed: 12/29/2022] Open
Affiliation(s)
- Marina Dokic
- Clinic of Hematology, Clinical Centre of Vojvodina, Hajduk Veljkova 1-8, Novi Sad, 21000 Serbia ; Medical Faculty, University of Novi Sad, Novi Sad, Serbia
| | - Ivana Urosevic
- Clinic of Hematology, Clinical Centre of Vojvodina, Hajduk Veljkova 1-8, Novi Sad, 21000 Serbia ; Medical Faculty, University of Novi Sad, Novi Sad, Serbia
| | - Ivanka Savic
- Clinic of Hematology, Clinical Centre of Vojvodina, Hajduk Veljkova 1-8, Novi Sad, 21000 Serbia
| | - Borivoj Sekulic
- Clinic of Hematology, Clinical Centre of Vojvodina, Hajduk Veljkova 1-8, Novi Sad, 21000 Serbia
| | - Aleksandar Savic
- Clinic of Hematology, Clinical Centre of Vojvodina, Hajduk Veljkova 1-8, Novi Sad, 21000 Serbia ; Medical Faculty, University of Novi Sad, Novi Sad, Serbia
| | - Ivana Milosevic
- Clinic of Hematology, Clinical Centre of Vojvodina, Hajduk Veljkova 1-8, Novi Sad, 21000 Serbia ; Medical Faculty, University of Novi Sad, Novi Sad, Serbia
| | - Nebojsa Rajic
- Clinic of Hematology, Clinical Centre of Vojvodina, Hajduk Veljkova 1-8, Novi Sad, 21000 Serbia
| |
Collapse
|
2
|
Jaitly V, Wang W, Hu S. Philadelphia chromosome-negative acute myeloid leukemia with 11q23/MLL translocation in a patient with chronic myelogenous leukemia. Stem Cell Investig 2015; 2:13. [PMID: 27358881 DOI: 10.3978/j.issn.2306-9759.2015.06.01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Accepted: 06/03/2015] [Indexed: 11/14/2022]
Abstract
Although defined by the presence of t(9;22), chronic myelogenous leukemia (CML) can have other concurrent additional cytogenetic changes, especially during disease progression. Additional chromosomal changes (ACAs) in CML often occur in Philadelphia chromosome (Ph)-positive cells and are associated with disease acceleration and treatment resistance. Occasionally chromosomal changes occur in Ph-negative cells and this phenomenon is often transient and does not correlate with disease progression. Very rarely myelodysplastic syndrome or acute leukemia can develop in Ph-negative cells. In this study, we report an unusual case of acute myeloid leukemia (AML) with 11q23/MLL translocation emerging from Ph-negative cells in a patient with CML.
Collapse
Affiliation(s)
- Vanya Jaitly
- Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Wei Wang
- Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Shimin Hu
- Department of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
3
|
Valent P, Bonnet D, Wöhrer S, Andreeff M, Copland M, Chomienne C, Eaves C. Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Res 2013; 73:1037-45. [PMID: 23345162 DOI: 10.1158/0008-5472.can-12-3678] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Accumulating evidence suggests that human cancers develop through a step-wise, but nonlinear process of cellular diversification and evolution. Recent mutational analyses indicate that this process is more complex and diverse than anticipated before whole-genome sequencing methods were readily available. Examples are also emerging now of genetically abnormal clones of cells that have acquired mutations with known oncogenic potential but, nevertheless, may show no manifestations of malignant change for many years. To accommodate these diverse realities, we suggest the term neoplastic refer to clones of cells that have any type of somatic aberrancy associated with an increased propensity to become malignant, and the derivative term neoplastic stem cell be adopted to identify the cells responsible for the long-term maintenance of such clones. Neoplastic clones would thus include those that never evolve further, as well as those that eventually give rise to fully malignant populations, and all stages in between. The term cancer stem cells would then be more appropriately restricted to cells generating subclones that have established malignant properties. More precise molecular understanding of the different stem cell states thus distinguished should contribute to the development of more effective prognostic and therapeutic tools for cancer diagnosis and treatment.
Collapse
Affiliation(s)
- Peter Valent
- Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
| | | | | | | | | | | | | |
Collapse
|
4
|
Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor. Ann Hematol 2012; 91:1825-6. [DOI: 10.1007/s00277-012-1477-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2012] [Accepted: 04/11/2012] [Indexed: 10/28/2022]
|
5
|
Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease. Leuk Res 2011; 35:1290-3. [DOI: 10.1016/j.leukres.2011.05.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2011] [Revised: 05/05/2011] [Accepted: 05/12/2011] [Indexed: 11/21/2022]
|
6
|
Santos FPS, Rodrigues M, Mac-Donald Bley do Nascimento C, Kerbauy FR, Ribeiro AAF, Mauro Kutner J, Hamerschlak N. Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib. Cytotherapy 2009; 12:113-5. [PMID: 19878083 DOI: 10.3109/14653240903300666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
7
|
Fava C, Cortes J. Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia. Am J Hematol 2008; 83:755. [PMID: 18615551 DOI: 10.1002/ajh.21230] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
MESH Headings
- Aged
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/therapeutic use
- Benzamides
- Chromosome Aberrations
- Chromosomes, Human, Pair 13/genetics
- Clone Cells/ultrastructure
- Fatal Outcome
- Humans
- Imatinib Mesylate
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/etiology
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/genetics
- Leukemia, Myeloid, Chronic-Phase/drug therapy
- Male
- Neoplasms, Second Primary/chemically induced
- Neoplasms, Second Primary/genetics
- Piperazines/adverse effects
- Piperazines/therapeutic use
- Pyrimidines/adverse effects
- Pyrimidines/therapeutic use
- Trisomy
Collapse
|
8
|
Chronic Myeloid Leukemia. Oncology 2007. [DOI: 10.1007/0-387-31056-8_66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Pawarode A, Sait SNJ, Nganga A, Coignet LJ, Barcos M, Baer MR. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. Leuk Res 2007; 31:1589-92. [PMID: 17391756 DOI: 10.1016/j.leukres.2007.01.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2006] [Revised: 01/17/2007] [Accepted: 01/18/2007] [Indexed: 10/23/2022]
Abstract
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been reported in patients with secondary chromosome abnormalities. We report a patient who developed AML during imatinib treatment of Ph-positive CML despite a cytogenetic response and absence of secondary chromosome abnormalities. Thus, development of AML as a rare event in CML patients with cytogenetic responses to imatinib therapy does not depend on the development of secondary cytogenetic abnormalities.
Collapse
MESH Headings
- Adult
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/therapeutic use
- Base Sequence
- Benzamides
- DNA Primers
- DNA, Complementary
- Female
- Humans
- Imatinib Mesylate
- In Situ Hybridization, Fluorescence
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myeloid, Acute/chemically induced
- Leukemia, Myeloid, Acute/complications
- Leukemia, Myeloid, Acute/genetics
- Piperazines/adverse effects
- Piperazines/therapeutic use
- Pyrimidines/adverse effects
- Pyrimidines/therapeutic use
Collapse
Affiliation(s)
- Attaphol Pawarode
- Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | | | | | | | | | | |
Collapse
|
10
|
Assouline S, Benemacher V, Gambacorti-Passerini C. Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient. Am J Hematol 2006; 81:646. [PMID: 16823818 DOI: 10.1002/ajh.20629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
MESH Headings
- Aged
- Benzamides
- Cytogenetic Analysis
- Diagnosis, Differential
- Female
- Follow-Up Studies
- Humans
- Hydroxyurea/therapeutic use
- Imatinib Mesylate
- In Situ Hybridization, Fluorescence
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Neoplasms, Multiple Primary/diagnosis
- Neoplasms, Multiple Primary/drug therapy
- Neoplasms, Multiple Primary/genetics
- Piperazines/therapeutic use
- Pyrimidines/therapeutic use
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
|
11
|
Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108:2811-3. [PMID: 16809614 DOI: 10.1182/blood-2006-04-017400] [Citation(s) in RCA: 129] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria. We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other 2 developed high-risk MDS that rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib.
Collapse
MESH Headings
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/therapeutic use
- Benzamides
- Chromosome Aberrations
- Female
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myeloid, Acute/etiology
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/drug therapy
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/genetics
- Male
- Middle Aged
- Myelodysplastic Syndromes/etiology
- Myelodysplastic Syndromes/genetics
- Piperazines/adverse effects
- Piperazines/therapeutic use
- Pyrimidines/adverse effects
- Pyrimidines/therapeutic use
- Risk Factors
Collapse
Affiliation(s)
- Craig Kovitz
- Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
| | | | | | | | | |
Collapse
|
12
|
Gargallo P, Cacchione R, Chena C, Dupont J, Garay G, Riveros D, Larripa I, Slavutsky I. Chronic lymphocytic leukemia developing in a patient with chronic myeloid leukemia: evidence of distinct lineage-associated genomic events. ACTA ACUST UNITED AC 2005; 161:74-7. [PMID: 16080961 DOI: 10.1016/j.cancergencyto.2005.01.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2004] [Accepted: 01/11/2005] [Indexed: 11/20/2022]
Abstract
We describe the cytogenetic, fluorescence in situ hybridization (FISH), and molecular findings in a patient who developed a typical chronic lymphocytic leukemia (CLL) 20 months after the diagnosis of a Philadelphia (Ph)-positive chronic myeloid leukemia. Unstimulated bone marrow culture showed a 46,XX,t(9;22)(q34;q11) karyotype, and interphase FISH detected the presence of a BCR/ABL fusion signal in 13% of cells. On stimulated bone marrow culture, a normal karyotype and a 13q14 deletion by interphase FISH with D13S319 probe in 14% of the cells were found. Molecular studies detected the chimeric BCR/ABL messengers by nested reverse-transcriptase polymerase chain reaction. The B-cellular clone was documented by the presence of a clonal heavy chain immunoglobulin rearrangement. The coexistence of these two hematologic malignancies leads to questions about their cell(s) of origin. We provide evidence that CLL arose in a Ph-negative clone. The implications of these findings are discussed.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- B-Lymphocytes/pathology
- Cell Lineage
- Chromosome Aberrations
- Chromosomes, Human, Pair 22/genetics
- Chromosomes, Human, Pair 9/genetics
- Female
- Fusion Proteins, bcr-abl/genetics
- Gene Rearrangement
- Humans
- Immunoglobulin Heavy Chains
- In Situ Hybridization, Fluorescence
- Karyotyping
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Neoplasms, Second Primary/genetics
- Neoplasms, Second Primary/pathology
- Philadelphia Chromosome
- Translocation, Genetic/genetics
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- Patricia Gargallo
- Departamento de Genética, Academia Nacional de Medicina, Pacheco de Melo 3081, Buenos Aires 1425, Argentina
| | | | | | | | | | | | | | | |
Collapse
|